Actively Recruiting

Age: 18Years +
All Genders
ID07230691

Observational Study of Clinical Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients Treated with Amivantamab-Containing Regimens Under Routine Clinical Practice

Led by Janssen Research & Development, LLC · Updated on 2026-06-05

380

Participants Needed

70

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the outcomes of treatments containing amivantamab for people with advanced non-small cell lung cancer (NSCLC) that have specific mutations in the epidermal growth factor receptor (EGFR) gene. This research focuses on patients with common EGFR mutations, including exon 19 deletions or exon 21 L858R substitutions, to understand how these regimens perform in real-world medical practice. The study aims to capture clinical and health-related results for this serious lung cancer type, particularly when it has spread to other parts of the body. The study observes two groups of participants receiving amivantamab-based treatments as part of their standard care. One group includes patients treated with amivantamab combined with carboplatin and pemetrexed after previous therapy has failed. The other group involves participants receiving amivantamab with lazertinib as their first-line therapy. No study drugs are provided; instead, researchers collect data from routine clinical visits, tracking how patients are treated according to usual medical practice. Participants are monitored for up to about 60 months to gather information on how long they continue treatment, progression-free survival, overall survival, and time to next treatment. Researchers also record adverse events, dose changes, use of other medications, and quality of life using specific questionnaires. This long-term observation helps to understand treatment impact and safety in everyday clinical settings without additional interventions or procedures beyond standard care.

CONDITIONS

Brief Title

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant has a confirmed diagnosis of common EGFR-mutated non-small cell lung cancer (exon 19 deletions or exon 21 L858R substitution)
  • Eligible for an amivantamab-containing regimen according to treating physician and local approved indications
  • Participant or legal representative must sign informed consent allowing data verification
  • Planned initiation of amivantamab-containing regimen for the first time within 4 weeks of data collection start
  • Decision to use amivantamab-containing regimen made before enrollment and separate from study inclusion decision
Not Eligible

You will not qualify if you...

  • Receiving active systemic anticancer treatment for advanced NSCLC not included in approved amivantamab combination regimen at treatment start (one cycle of platinum-based chemotherapy allowed before amivantamab in first-line therapy)
  • Prior amivantamab treatment in clinical trial or compassionate use
  • Receiving biosimilar or non-original biologic agents instead of amivantamab
  • Any conditions listed as contraindications in the summary of product characteristics for amivantamab or agents required in the treatment regimen (lazertinib, platinum, pemetrexed)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to approximately 60 months

Participants who undergo routine care with amivantamab-containing regimens are observed to collect data on clinical outcomes and quality of life.

Visits as per routine clinical practice

Trial Site Locations

Total: 70 locations

1

University Hospital Graz

Graz, Austria, 8036

Actively Recruiting

2

Klinikum Klagenfurt am Worthersee

Klagenfurt, Austria, 9020

Actively Recruiting

3

UZ Brussel

Brussels, Belgium, 1090

Actively Recruiting

4

UZ Antwerpen

Edegem, Belgium, 2650

Actively Recruiting

5

Jessa Ziekenhuis

Hasselt, Belgium, 3500

Actively Recruiting

6

Az Groeninge

Kortrijk, Belgium, 8500

Actively Recruiting

7

Chu Helora Hospital La Louviere Site Jolimont

La Louvière, Belgium, 7100

Actively Recruiting

8

CHU de Liege

Liège, Belgium, 4000

Actively Recruiting

9

Vitaz

Sint-Niklaas, Belgium, 9100

Actively Recruiting

10

Fakultni nemocnice Brno

Brno, Czechia, 625 00

Actively Recruiting

11

Fakultni nemocnice Hradec Kralove

Hradec Králové, Czechia, 500 05

Actively Recruiting

12

Fakultni nemocnice Olomouc

Olomouc, Czechia, 77900

Actively Recruiting

13

Fakultni Thomayerova nemocnice

Prague, Czechia, 140 59

Actively Recruiting

14

MVZ am Klinikum Aschaffenburg Onkologie

Aschaffenburg, Germany, 63739

Actively Recruiting

15

Evangelisches Klinikum Bethel

Bielefeld, Germany, 33611

Actively Recruiting

16

Augusta Kliniken Bochum Hattingen

Bochum, Germany, 44791

Actively Recruiting

17

Klinikum Chemnitz gGmbH

Chemnitz, Germany, 09113

Actively Recruiting

18

Haematologie u Onkologie Koeln MV Zentrum

Cologne, Germany, 50677

Actively Recruiting

19

Kliniken der Stadt Köln gGmbH, Krankenhaus Köln-Mehrheim

Cologne, Germany, 51109

Actively Recruiting

20

Kliniken Essen-Mitte; Evangelische Huyssens-Stiftung

Essen, Germany, 45136

Actively Recruiting

21

Facharztzentrum Eppendorf

Hamburg, Germany, 20249

Actively Recruiting

22

Onkologie am Raschplatz

Hanover, Germany, 30161

Actively Recruiting

23

Klinikum Region Hannover Klinikum Siloah

Hanover, Germany, 30449

Actively Recruiting

24

Lungenklinik Hemer

Hemer, Germany, 58675

Actively Recruiting

25

Klinikum Konstanz

Konstanz, Germany, 78464

Actively Recruiting

26

MVZ fur Hamatologie und Onkologie Rhein Kreis GmbH

Neuss, Germany, 41462

Actively Recruiting

27

Knappschaft Kliniken MVZ Nord GmbH

Recklinghausen, Germany, 45659

Actively Recruiting

28

MVZ Onkologie Groschek Keller

Stolberg, Germany, 52222

Actively Recruiting

29

Bundeswehrkrankenhaus Ulm

Ulm, Germany, 89081

Actively Recruiting

30

Rabin Medical Center

Petah Tikva, Israel, 4941492

Actively Recruiting

31

Sheba Medical Center

Ramat Gan, Israel, 5262000

Actively Recruiting

32

Assuta MC

Tel Aviv, Israel, 6971028

Actively Recruiting

33

Ospedale San Giuseppe Moscati di Avellino

Avellino, Italy, 83100

Actively Recruiting

34

Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II

Bari, Italy, 70124

Actively Recruiting

35

ASST Spedali Civili Brescia

Brescia, Italy, 25123

Actively Recruiting

36

Istituto di Candiolo, IRCCS

Candiolo, Italy, 10060

Actively Recruiting

37

PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania

Catania, Italy, 95123

Actively Recruiting

38

Azienda Ospedaliera Pugliese Ciaccio Catanzaro

Catanzaro, Italy, 88100

Actively Recruiting

39

Ospedale Policlinico San Martino IRCCS

Genova, Italy, 16132

Actively Recruiting

40

Azienda Ospedaliera ''Vito Fazzi''

Lecce, Italy, 73100

Actively Recruiting

41

San Raffaele Hospital

Milan, Italy, 20132

Actively Recruiting

42

Istituto Dei Tumori Di Milano

Milan, Italy, 20133

Actively Recruiting

43

European Institute of Oncology

Milan, Italy, 20141

Actively Recruiting

44

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy, 20162

Actively Recruiting

45

Fondazione G Pascale Istituto Nazionale Tumori IRCCS

Naples, Italy, 80131

Actively Recruiting

46

Azienda Ospedaliero Universitaria Maggiore della Carita di Novara

Novara, Italy, 28100

Actively Recruiting

47

ASL Gallura - Ospedale Giovanni Paolo II

Olbia, Italy, 07026

Actively Recruiting

48

Aou San Luigi Gonzaga

Orbassano, Italy, 10043

Actively Recruiting

49

Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone

Palermo, Italy, 90127

Actively Recruiting

50

A.O.R Villa Sofia Cervello

Palermo, Italy, 90146

Actively Recruiting

51

Azienda Ospedaliero-Universitaria Di Parma

Parma, Italy, 43126

Actively Recruiting

52

Fondazione Policlinico Universitario A Gemelli IRCCS

Roma, Italy, 00168

Actively Recruiting

53

Campus Bio Medico di Roma

Roma, Italy, 128

Actively Recruiting

54

Azienda Ospedaliero Universitaria di Sassari

Sassari, Italy, 07100

Actively Recruiting

55

Ospedali Riuniti Di Ancona

Torrette-Ancona, Italy, 60126

Actively Recruiting

56

Hosp Reina Sofia

Córdoba, Spain, 14004

Actively Recruiting

57

Hosp. de Jerez de La Frontera

Jerez de la Frontera, Spain, 11407

Actively Recruiting

58

Hosp. Univ. Lucus Augusti

Lugo, Spain, 27003

Actively Recruiting

59

Complexo Hosp. Univ. de Ourense

Ourense, Spain, 32005

Actively Recruiting

60

Hosp. Univ. Son Espases

Palma de Mallorca, Spain, 07120

Actively Recruiting

61

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, Spain, 15706

Actively Recruiting

62

Hospital Universitario Virgen Rocio

Seville, Spain, 41013

Actively Recruiting

63

Hosp. Clinico Univ. de Valladolid

Valladolid, Spain, 47003

Actively Recruiting

64

Royal United Hospital

Bath, United Kingdom, BA1 3NG

Actively Recruiting

65

Eastbourne District General Hospital

Eastbourne, United Kingdom, BN21 2UD

Actively Recruiting

66

Royal Surrey County Hospital NHS Trust

Guildford, United Kingdom, GU2 7XX

Actively Recruiting

67

New Cross Hospital

Heath Town, United Kingdom, WV10 0QP

Actively Recruiting

68

Royal Marsden Hospital

London, United Kingdom, SW3 6JJ

Actively Recruiting

69

The Christie NHS Foundation Trust Christie Hospital

Manchester, United Kingdom, M20 4BX

Actively Recruiting

70

Royal Marsden Hospital (Sutton)

Sutton, United Kingdom, SM2 5PT

Actively Recruiting

Loading map...

Research Team

S

Study Contact

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase I/II Trial of UCB4594 to Assess Safety, Pharmacokine...

Advanced Solid Tumours

Actively Recruiting

4 locations

A Real World Study of Ensartinib in Advanced ALK-positive No...

Carcinoma, Non-Small-Cell Lung

Actively Recruiting

1 location

A Phase 1, Randomized, Double-blind Study Comparing Pharmaco...

Carcinoma, Non-Small-Cell Lung

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here